{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:22:20Z","timestamp":1785291740920,"version":"3.55.0"},"reference-count":190,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-024-03179-6","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T16:02:02Z","timestamp":1718899322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Orbital histiocytosis; From A to Z"],"prefix":"10.1007","volume":"44","author":[{"given":"Mohammad Taher","family":"Rajabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Abdol Homayuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Samiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheida","family":"Mobader Sani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hossein","family":"Aghajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohsen","family":"Rafizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobina","family":"Amanollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saharnaz","family":"Pezeshgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Simindokht","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Bagher","family":"Rajabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8064-3545","authenticated-orcid":false,"given":"Reza","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"issue":"7","key":"3179_CR1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36(7):1703\u20131719","journal-title":"Leukemia"},{"issue":"1","key":"3179_CR2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0889-8588(18)30682-8","volume":"1","author":"DM Komp","year":"1987","unstructured":"Komp DM (1987) Historical perspectives of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1(1):9\u201321","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"3179_CR3","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJMra1607548","volume":"379","author":"CE Allen","year":"2018","unstructured":"Allen CE, Merad M, McClain KL (2018) Langerhans-cell histiocytosis. N Engl J Med 379(9):856\u2013868","journal-title":"N Engl J Med"},{"issue":"5","key":"3179_CR4","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bjh.18459","volume":"199","author":"H Liu","year":"2022","unstructured":"Liu H et al (2022) Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: a national registry study from England, 2013\u20132019. Br J Haematol 199(5):728\u2013738","journal-title":"Br J Haematol"},{"issue":"1","key":"3179_CR5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/pbc.21498","volume":"51","author":"A Guyot-Goubin","year":"2008","unstructured":"Guyot-Goubin A et al (2008) Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000\u20132004. Pediatr Blood Cancer 51(1):71\u201375","journal-title":"Pediatr Blood Cancer"},{"issue":"26","key":"3179_CR6","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1182\/blood-2018-03-839753","volume":"131","author":"O Abla","year":"2018","unstructured":"Abla O et al (2018) Consensus recommendations for the diagnosis and clinical management of Rosai\u2013Dorfman\u2013Destombes disease. Blood 131(26):2877\u20132890","journal-title":"Blood"},{"issue":"22","key":"3179_CR7","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","volume":"127","author":"JF Emile","year":"2016","unstructured":"Emile JF et al (2016) Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127(22):2672\u20132681","journal-title":"Blood"},{"issue":"10295","key":"3179_CR8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(21)00311-1","volume":"398","author":"J-F Emile","year":"2021","unstructured":"Emile J-F et al (2021) Histiocytosis. Lancet 398(10295):157\u2013170","journal-title":"Lancet"},{"key":"3179_CR9","doi-asserted-by":"crossref","unstructured":"Rajabi MT et al (2023) Orbital histiocytosis and fibrohistiocytosis: the clinicopathological characteristics of 117 patients, over a decade of experience. Int Ophthalmol","DOI":"10.1007\/s10792-023-02903-y"},{"issue":"8526","key":"3179_CR10","first-page":"208","volume":"1","author":"Histiocytosis syndromes in children","year":"1987","unstructured":"Histiocytosis syndromes in children (1987) Writing group of the histiocyte society. Lancet 1(8526):208\u2013209","journal-title":"Lancet"},{"key":"3179_CR11","first-page":"931","volume":"42","author":"JA Shields","year":"1990","unstructured":"Shields JA, Shields CL (1990) Clinical spectrum of histiocytic tumors of the orbit. Trans Pa Acad Ophthalmol Otolaryngol 42:931\u2013937","journal-title":"Trans Pa Acad Ophthalmol Otolaryngol"},{"issue":"3","key":"3179_CR12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1590\/S0004-27492008000300019","volume":"71","author":"EF Marback","year":"2008","unstructured":"Marback EF et al (2008) Orbital eosinophilic granuloma. Arq Bras Oftalmol 71(3):405\u2013409","journal-title":"Arq Bras Oftalmol"},{"issue":"1","key":"3179_CR13","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1002\/hed.23396","volume":"36","author":"A Karligkiotis","year":"2014","unstructured":"Karligkiotis A et al (2014) Primary orbital eosinophilic angiocentric fibrosis with intranasal extension. Head Neck 36(1):E8-e11","journal-title":"Head Neck"},{"issue":"3","key":"3179_CR14","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/j.jcjo.2020.11.009","volume":"56","author":"A Grosinger","year":"2021","unstructured":"Grosinger A, Garrity JA, Salom\u00e3o DR (2021) Follicular dendritic cell sarcoma: a novel orbital tumour. Can J Ophthalmol 56(3):e84\u2013e86","journal-title":"Can J Ophthalmol"},{"issue":"6","key":"3179_CR15","first-page":"1258","volume":"16","author":"WK Erly","year":"1995","unstructured":"Erly WK, Carmody RF, Dryden RM (1995) Orbital histiocytosis X. AJNR Am J Neuroradiol 16(6):1258\u20131261","journal-title":"AJNR Am J Neuroradiol"},{"issue":"11","key":"3179_CR16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/jclinpath-2020-206733","volume":"73","author":"C Bruce-Brand","year":"2020","unstructured":"Bruce-Brand C, Schneider JW, Schubert P (2020) Rosai\u2013Dorfman disease: an overview. J Clin Pathol 73(11):697\u2013705","journal-title":"J Clin Pathol"},{"issue":"6","key":"3179_CR17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4321\/S0365-66912005000600005","volume":"80","author":"G Blanco Mateos","year":"2005","unstructured":"Blanco Mateos G (2005) Orbital xanthogranulomatosis. Arch Soc Esp Oftalmol 80(6):329\u2013330","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"1","key":"3179_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41590-019-0558-z","volume":"21","author":"CE Allen","year":"2020","unstructured":"Allen CE et al (2020) The coming of age of Langerhans cell histiocytosis. Nat Immunol 21(1):1\u20137","journal-title":"Nat Immunol"},{"issue":"3","key":"3179_CR19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0161-6420(86)33731-X","volume":"93","author":"JA Shields","year":"1986","unstructured":"Shields JA et al (1986) Space-occupying orbital masses in children: a review of 250 consecutive biopsies. Ophthalmology 93(3):379\u2013384","journal-title":"Ophthalmology"},{"issue":"11","key":"3179_CR20","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","volume":"116","author":"G Badalian-Very","year":"2010","unstructured":"Badalian-Very G et al (2010) Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116(11):1919\u20131923","journal-title":"Blood"},{"issue":"4","key":"3179_CR21","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1084\/jem.20130977","volume":"211","author":"ML Berres","year":"2014","unstructured":"Berres ML et al (2014) BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 211(4):669\u2013683","journal-title":"J Exp Med"},{"key":"3179_CR22","doi-asserted-by":"crossref","unstructured":"Roden AC et al (2014) BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Am J Surg Pathol 38(4)","DOI":"10.1097\/PAS.0000000000000129"},{"key":"3179_CR23","doi-asserted-by":"crossref","unstructured":"Go H et al (2014) Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology 65","DOI":"10.1111\/his.12416"},{"issue":"13","key":"3179_CR24","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2012-05-430140","volume":"120","author":"J Haroche","year":"2012","unstructured":"Haroche J et al (2012) High prevalence of BRAF V600E mutations in Erdheim\u2013Chester disease but not in other non-Langerhans cell histiocytoses. Blood 120(13):2700\u20132703","journal-title":"Blood"},{"key":"3179_CR25","doi-asserted-by":"crossref","first-page":"1275085","DOI":"10.3389\/fimmu.2023.1275085","volume":"14","author":"T Sconocchia","year":"2023","unstructured":"Sconocchia T et al (2023) Langerhans cell histiocytosis: current advances in molecular pathogenesis. Front Immunol 14:1275085","journal-title":"Front Immunol"},{"issue":"16","key":"3179_CR26","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/blood-2014-08-596080","volume":"124","author":"M Kobayashi","year":"2014","unstructured":"Kobayashi M, Tojo A (2014) The BRAF-V600E mutation in circulating cell-free DNA is a promising biomarker of high-risk adult Langerhans cell histiocytosis. Blood 124(16):2610\u20132611","journal-title":"Blood"},{"issue":"4","key":"3179_CR27","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/bjh.15577","volume":"183","author":"S H\u00e9ritier","year":"2018","unstructured":"H\u00e9ritier S et al (2018) Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study. Br J Haematol 183(4):608\u2013617","journal-title":"Br J Haematol"},{"issue":"1","key":"3179_CR28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjh.13247","volume":"169","author":"ML Berres","year":"2015","unstructured":"Berres ML, Merad M, Allen CE (2015) Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol 169(1):3\u201313","journal-title":"Br J Haematol"},{"issue":"10","key":"3179_CR29","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2014-05-577361","volume":"124","author":"NA Brown","year":"2014","unstructured":"Brown NA et al (2014) High prevalence of somatic MAP2K1 mutations in BRAF V600E\u2013negative Langerhans cell histiocytosis. Blood 124(10):1655\u20131658","journal-title":"Blood"},{"issue":"19","key":"3179_CR30","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","volume":"124","author":"R Chakraborty","year":"2014","unstructured":"Chakraborty R et al (2014) Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 124(19):3007\u20133015","journal-title":"Blood"},{"issue":"20","key":"3179_CR31","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1182\/blood-2013-06-511139","volume":"123","author":"DS Nelson","year":"2014","unstructured":"Nelson DS et al (2014) Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood 123(20):3152\u20133155","journal-title":"Blood"},{"issue":"6","key":"3179_CR32","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/gcc.22247","volume":"54","author":"DS Nelson","year":"2015","unstructured":"Nelson DS et al (2015) MAP2K1 and MAP3K1 mutations in langerhans cell histiocytosis. Genes Chromosom Cancer 54(6):361\u2013368","journal-title":"Genes Chromosom Cancer"},{"issue":"4","key":"3179_CR33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/PAT.0000000000000256","volume":"47","author":"DE Demellawy","year":"2015","unstructured":"Demellawy DE et al (2015) Langerhans cell histiocytosis: a comprehensive review. Pathology 47(4):294\u2013301","journal-title":"Pathology"},{"key":"3179_CR34","unstructured":"Zinn DJ, Chakraborty R, Allen CE (2016) Langerhans cell histiocytosis: emerging insights and clinical implications. Oncology (Williston Park, N.Y.) 30(2):122\u2013132, 139"},{"issue":"2","key":"3179_CR35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2350\/09-05-0651-OA.1","volume":"13","author":"ML Galluzzo","year":"2010","unstructured":"Galluzzo ML et al (2010) Bone marrow findings at diagnosis in patients with multisystem langerhans cell histiocytosis. Pediatr Dev Pathol 13(2):101\u2013106","journal-title":"Pediatr Dev Pathol"},{"issue":"3","key":"3179_CR36","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1525-1470.2008.00669.x","volume":"25","author":"EK Satter","year":"2008","unstructured":"Satter EK, High WA (2008) Langerhans cell histiocytosis: a review of the current recommendations of the histiocyte society. Pediatr Dermatol 25(3):291\u2013295","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"3179_CR37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-8-72","volume":"8","author":"M Girschikofsky","year":"2013","unstructured":"Girschikofsky M et al (2013) Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis 8(1):72","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3179_CR38","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1148\/rg.284085013","volume":"28","author":"EM Chung","year":"2008","unstructured":"Chung EM et al (2008) From the archives of the AFIP. Pediatric orbit tumors and tumorlike lesions: osseous lesions of the orbit. Radiographics 28(4):1193\u20131214","journal-title":"Radiographics"},{"issue":"2\u20133","key":"3179_CR39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.neuchi.2010.02.017","volume":"56","author":"P Chastagner","year":"2010","unstructured":"Chastagner P (2010) Malignant extraconal tumors of the orbit in childhood. Neurochirurgie 56(2\u20133):281\u2013286","journal-title":"Neurochirurgie"},{"issue":"4 Suppl","key":"3179_CR40","first-page":"964","volume":"16","author":"JS Stromberg","year":"1995","unstructured":"Stromberg JS et al (1995) Langerhans cell histiocytosis involving the sphenoid sinus and superior orbital fissure. AJNR Am J Neuroradiol 16(4 Suppl):964\u2013967","journal-title":"AJNR Am J Neuroradiol"},{"issue":"3","key":"3179_CR41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/01676830600669486","volume":"25","author":"LJ Maccheron","year":"2006","unstructured":"Maccheron LJ et al (2006) Ocular adnexal Langerhans cell histiocytosis clinical features and management. Orbit 25(3):169\u2013177","journal-title":"Orbit"},{"issue":"1","key":"3179_CR42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12886-019-1269-9","volume":"19","author":"C Wu","year":"2019","unstructured":"Wu C et al (2019) MR imaging features of orbital Langerhans cell Histiocytosis. BMC Ophthalmol 19(1):263","journal-title":"BMC Ophthalmol"},{"key":"3179_CR43","unstructured":"Harris GJ, Woo KI (2003) Eosinophilic granuloma of the orbit: a paradox of aggressive destruction responsive to minimal intervention. Trans Am Ophthalmol Soc 101:93\u2013103; discussion 103\u20135"},{"issue":"2","key":"3179_CR44","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/pbc.24367","volume":"60","author":"R Haupt","year":"2013","unstructured":"Haupt R et al (2013) Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer 60(2):175\u2013184","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"3179_CR45","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/bjh.14818","volume":"182","author":"G Goyal","year":"2018","unstructured":"Goyal G et al (2018) Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes. Br J Haematol 182(4):579\u2013581","journal-title":"Br J Haematol"},{"key":"3179_CR46","doi-asserted-by":"crossref","unstructured":"Ribeiro K et al (2015) Ethnicity, race, and socioeconomic status influence incidence of Langerhans cell histiocytosis: Variations in the Incidence of LCH. Pediatric Blood cancer 62","DOI":"10.1002\/pbc.25404"},{"issue":"5","key":"3179_CR47","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jpeds.2008.05.002","volume":"153","author":"M Minkov","year":"2008","unstructured":"Minkov M et al (2008) Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry. J Pediatr 153(5):700-705.e2","journal-title":"J Pediatr"},{"issue":"9","key":"3179_CR48","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/archdischild-2016-312185","volume":"102","author":"C Tin Wai","year":"2017","unstructured":"Tin Wai C et al (2017) Late outcomes in children with Langerhans cell histiocytosis. Arch Dis Child 102(9):830","journal-title":"Arch Dis Child"},{"issue":"6","key":"3179_CR49","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/bjh.14140","volume":"174","author":"C Rigaud","year":"2016","unstructured":"Rigaud C et al (2016) Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. Br J Haematol 174(6):887\u2013898","journal-title":"Br J Haematol"},{"issue":"25","key":"3179_CR50","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1182\/blood-2012-09-455774","volume":"121","author":"H Gadner","year":"2013","unstructured":"Gadner H et al (2013) Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood 121(25):5006\u20135014","journal-title":"Blood"},{"issue":"5","key":"3179_CR51","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/0194599815598969","volume":"153","author":"A Bezdjian","year":"2015","unstructured":"Bezdjian A et al (2015) Isolated Langerhans cell histiocytosis bone lesion in pediatric patients: systematic review and treatment algorithm. Otolaryngol Head Neck Surg 153(5):751\u2013757","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"2","key":"3179_CR52","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0889-8588(05)70514-1","volume":"12","author":"RJ Arceci","year":"1998","unstructured":"Arceci RJ, Brenner MK, Pritchard J (1998) Controversies and new approaches to treatment of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 12(2):339\u2013357","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"3179_CR53","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4103\/ojo.OJO_161_2016","volume":"11","author":"S Singh","year":"2018","unstructured":"Singh S et al (2018) Langerhans cell histiocytosis of the orbit: A study of eight cases. Oman J Ophthalmol 11(2):134\u2013139","journal-title":"Oman J Ophthalmol"},{"issue":"3","key":"3179_CR54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.10053","volume":"69","author":"C Rodriguez-Galindo","year":"2002","unstructured":"Rodriguez-Galindo C et al (2002) Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. Am J Hematol 69(3):179\u2013184","journal-title":"Am J Hematol"},{"key":"3179_CR55","doi-asserted-by":"crossref","unstructured":"Abraham A et al (2013) Clofarabine salvage therapy for refractory high-risk Langerhans cell histiocytosis. Pediatr Blood Cancer 60","DOI":"10.1002\/pbc.24436"},{"issue":"3","key":"3179_CR56","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/pbc.24772","volume":"61","author":"SJ Simko","year":"2014","unstructured":"Simko SJ et al (2014) Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai\u2013Dorfman disease. Pediatr Blood Cancer 61(3):479\u2013487","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"3179_CR57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/mpo.2950250204","volume":"25","author":"RB Womer","year":"1995","unstructured":"Womer RB, Anunciato KR, Chehrenama M (1995) Oral methotrexate and alternate-day prednisone for low-risk Langerhans cell histiocytosis. Med Pediatr Oncol 25(2):70\u201373","journal-title":"Med Pediatr Oncol"},{"issue":"5","key":"3179_CR58","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1097\/MPH.0000000000000165001","volume":"36","author":"J Braier","year":"2014","unstructured":"Braier J et al (2014) Symptomatic bone Langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone. J Pediatr Hematol Oncol 36(5):e280\u2013e284","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"3179_CR59","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/cncr.21985","volume":"107","author":"A Morimoto","year":"2006","unstructured":"Morimoto A et al (2006) Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans cell histiocytosis study group-96 protocol study. Cancer 107(3):613\u2013619","journal-title":"Cancer"},{"issue":"20","key":"3179_CR60","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood-2016-06-721993","volume":"128","author":"DJ Zinn","year":"2016","unstructured":"Zinn DJ et al (2016) Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood 128(20):2462\u20132465","journal-title":"Blood"},{"issue":"9","key":"3179_CR61","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2012-07-446286","volume":"121","author":"J Haroche","year":"2013","unstructured":"Haroche J et al (2013) Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim\u2013Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 121(9):1495\u20131500","journal-title":"Blood"},{"issue":"3","key":"3179_CR62","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","volume":"4","author":"EL Diamond","year":"2018","unstructured":"Diamond EL et al (2018) Vemurafenib for BRAF V600-Mutant Erdheim\u2013Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, Open-label VE-BASKET study. JAMA Oncol 4(3):384\u2013388","journal-title":"JAMA Oncol"},{"issue":"5","key":"3179_CR63","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.2014.57.1950","volume":"33","author":"J Haroche","year":"2015","unstructured":"Haroche J et al (2015) Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim\u2013Chester disease. J Clin Oncol 33(5):411\u2013418","journal-title":"J Clin Oncol"},{"issue":"8","key":"3179_CR64","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman DM et al (2015) Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373(8):726\u2013736","journal-title":"N Engl J Med"},{"key":"3179_CR65","doi-asserted-by":"crossref","unstructured":"Diamond E et al (2019) Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature 567","DOI":"10.1038\/s41586-019-1012-y"},{"issue":"15","key":"3179_CR66","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2018-10-878363","volume":"133","author":"OS Eckstein","year":"2019","unstructured":"Eckstein OS et al (2019) Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. Blood 133(15):1691\u20131694","journal-title":"Blood"},{"issue":"31","key":"3179_CR67","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.19.00456","volume":"37","author":"J Donadieu","year":"2019","unstructured":"Donadieu J et al (2019) Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study. J Clin Oncol 37(31):2857\u20132865","journal-title":"J Clin Oncol"},{"issue":"15","key":"3179_CR68","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/bloodadvances.2022008414","volume":"7","author":"JA Whitlock","year":"2023","unstructured":"Whitlock JA et al (2023) Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis. Blood Adv 7(15):3806\u20133815","journal-title":"Blood Adv"},{"key":"3179_CR69","doi-asserted-by":"crossref","unstructured":"Cournoyer E et al (2023) Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders. Haematologica","DOI":"10.3324\/haematol.2023.283295"},{"issue":"6","key":"3179_CR70","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/0002-9394(65)92808-4","volume":"60","author":"LE Zimmerman","year":"1965","unstructured":"Zimmerman LE (1965) Ocular lesions of juvenile xanthogranuloma. Nevoxanthoedothelioma. Am J Ophthalmol 60(6):1011\u20131035","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"3179_CR71","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s00417-022-05560-6","volume":"260","author":"R Chen","year":"2022","unstructured":"Chen R et al (2022) On the knowledge of solitary juvenile xanthogranuloma of the eyelid: a case series and literature review. Graefes Arch Clin Exp Ophthalmol 260(7):2339\u20132345","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"3179_CR72","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0165-5876(94)01107-9","volume":"32","author":"B Benjamin","year":"1995","unstructured":"Benjamin B et al (1995) Benign juvenile xanthogranuloma of the larynx. Int J Pediatr Otorhinolaryngol 32(1):77\u201381","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"2","key":"3179_CR73","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000513940","volume":"56","author":"E Bilgin","year":"2021","unstructured":"Bilgin E, \u00d6kten AI (2021) Fatal disseminated multiple intracranial Juvenile xanthogranuloma without cutaneous and other organ involvement: a rare case report. Pediatr Neurosurg 56(2):166\u2013170","journal-title":"Pediatr Neurosurg"},{"issue":"13","key":"3179_CR74","first-page":"635","volume":"145","author":"LE Br\u00f6ker","year":"2001","unstructured":"Br\u00f6ker LE et al (2001) Juvenile xanthogranuloma: a form of histiocytosis with an excellent prognosis. Ned Tijdschr Geneeskd 145(13):635\u2013639","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"1","key":"3179_CR75","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s40478-019-0811-6","volume":"7","author":"J Picarsic","year":"2019","unstructured":"Picarsic J et al (2019) BRAF V600E mutation in Juvenile xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim\u2013Chester disease. Acta Neuropathol Commun 7(1):168","journal-title":"Acta Neuropathol Commun"},{"key":"3179_CR76","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/asheducation-2015.1.571","volume":"2015","author":"J Haroche","year":"2015","unstructured":"Haroche J, Abla O (2015) Uncommon histiocytic disorders: Rosai\u2013Dorfman, juvenile xanthogranuloma, and Erdheim\u2013Chester disease. Hematology Am Soc Hematol Educ Program 2015:571\u2013578","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"3179_CR77","doi-asserted-by":"crossref","first-page":"229","DOI":"10.22336\/rjo.2017.41","volume":"61","author":"A Pantalon","year":"2017","unstructured":"Pantalon A et al (2017) Iris juvenile xanthogranuloma in an infant\u2014spontaneous hyphema and secondary glaucoma. Rom J Ophthalmol 61(3):229\u2013236","journal-title":"Rom J Ophthalmol"},{"issue":"10","key":"3179_CR78","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.ophtha.2015.06.009","volume":"122","author":"WA Samara","year":"2015","unstructured":"Samara WA et al (2015) Juvenile xanthogranuloma involving the eye and ocular adnexa: tumor control, visual outcomes, and globe salvage in 30 patients. Ophthalmology 122(10):2130\u20132138","journal-title":"Ophthalmology"},{"issue":"5","key":"3179_CR79","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00000478-200305000-00003","volume":"27","author":"LP Dehner","year":"2003","unstructured":"Dehner LP (2003) Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol 27(5):579\u2013593","journal-title":"Am J Surg Pathol"},{"key":"3179_CR80","doi-asserted-by":"crossref","unstructured":"Samara WA et al (2015) Multimodal imaging for detection of clinically inapparent diffuse iris juvenile xanthogranuloma. J Pediatr Ophthalmol Strabismus 52 Online:p. e30\u2013e33","DOI":"10.3928\/01913913-20150506-01"},{"issue":"1","key":"3179_CR81","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/tjo.tjo_35_21","volume":"13","author":"SE Anilkumar","year":"2023","unstructured":"Anilkumar SE et al (2023) Unusual presentation of a vascularized iris lesion in an infant. Taiwan J Ophthalmol 13(1):117\u2013120","journal-title":"Taiwan J Ophthalmol"},{"issue":"1","key":"3179_CR82","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3928\/0191-3913-19970101-10","volume":"34","author":"ZA Karcioglu","year":"1997","unstructured":"Karcioglu ZA, Mullaney PB (1997) Diagnosis and management of iris juvenile xanthogranuloma. J Pediatr Ophthalmol Strabismus 34(1):44\u201351","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"4","key":"3179_CR83","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0002-9394(67)91301-3","volume":"63","author":"PM Gaynes","year":"1967","unstructured":"Gaynes PM, Cohen GS (1967) Juvenile xanthogranuloma of the orbit. Am J Ophthalmol 63(4):755\u2013757","journal-title":"Am J Ophthalmol"},{"key":"3179_CR84","doi-asserted-by":"crossref","unstructured":"Sanders TE (1966) Infantile xanthogranuloma of the orbit. A report of three cases. Am J Ophthalmol 61(5 Pt 2):1299\u20131306","DOI":"10.1016\/0002-9394(66)90259-5"},{"key":"3179_CR85","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2214\/ajr.95.1.52","volume":"95","author":"JL Eller","year":"1965","unstructured":"Eller JL (1965) Roentgen therapy for visceral Juvenile xanthogranuloma, including a case with involvement of the heart. Am J Roentgenol Radium Ther Nucl Med 95:52\u201355","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"issue":"6","key":"3179_CR86","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1097\/OPX.0000000000000609","volume":"92","author":"L Niu","year":"2015","unstructured":"Niu L et al (2015) Ocular juvenile xanthogranuloma. Optom Vis Sci 92(6):e126\u2013e133","journal-title":"Optom Vis Sci"},{"issue":"6","key":"3179_CR87","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaapos.2011.07.011","volume":"15","author":"S Longmuir","year":"2011","unstructured":"Longmuir S et al (2011) Juvenile xanthogranulomatosis with bilateral and multifocal ocular lesions of the iris, cornealscleral limbus, and choroid. J Am Assoc Pediatr Ophthalmol Strabismus 15(6):598\u2013600","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus"},{"issue":"3","key":"3179_CR88","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jaapos.2014.01.007","volume":"18","author":"N Ashkenazy","year":"2014","unstructured":"Ashkenazy N et al (2014) Successful treatment of juvenile xanthogranuloma using bevacizumab. J Am Assoc Pediatr Ophthalmol Strabismus 18(3):295\u2013297","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus"},{"issue":"5","key":"3179_CR89","first-page":"243","volume":"83","author":"A Asarch","year":"2009","unstructured":"Asarch A et al (2009) Cutaneous disseminated xanthogranuloma in an adult: case report and review of the literature. Cutis 83(5):243\u2013249","journal-title":"Cutis"},{"key":"3179_CR90","unstructured":"Jakobiec FA et al (1993) Periocular xanthogranulomas associated with severe adult-onset asthma. Trans Am Ophthalmol Soc 91:99\u2013125; discussion 125\u20139"},{"issue":"5","key":"3179_CR91","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1136\/bjo.2005.085894","volume":"90","author":"JA Sivak-Callcott","year":"2006","unstructured":"Sivak-Callcott JA et al (2006) Adult xanthogranulomatous disease of the orbit and ocular adnexa: new immunohistochemical findings and clinical review. Br J Ophthalmol 90(5):602\u2013608","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"3179_CR92","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/01.IOP.0000132177.20945.E9","volume":"20","author":"MD Hammond","year":"2004","unstructured":"Hammond MD et al (2004) Adult orbital xanthogranuloma with associated adult-onset asthma. Ophthalmic Plast Reconstr Surg 20(4):329\u2013332","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"5","key":"3179_CR93","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.oftal.2012.11.007","volume":"89","author":"E Sanz-Marco","year":"2014","unstructured":"Sanz-Marco E et al (2014) Necrobiotic xanthogranuloma. Differential diagnosis, treatment and systemic involvement. Case report. Arch Soc Esp Oftalmol 89(5):186\u2013189","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"8","key":"3179_CR94","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/bjo.2006.107821","volume":"91","author":"CI Zoumalan","year":"2007","unstructured":"Zoumalan CI et al (2007) Periorbital xanthogranuloma after blepharoplasty. Br J Ophthalmol 91(8):1088\u20131089","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"3179_CR95","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.det.2015.03.010","volume":"33","author":"J Kerstetter","year":"2015","unstructured":"Kerstetter J, Wang J (2015) Adult orbital xanthogranulomatous disease: a review with emphasis on etiology, systemic associations, diagnostic tools, and treatment. Dermatol Clin 33(3):457\u2013463","journal-title":"Dermatol Clin"},{"key":"3179_CR96","doi-asserted-by":"crossref","unstructured":"Ortiz Salvador JM, Subiabre Ferrer D, P\u00e9rez Ferriols A (2017) Adult xanthogranulomatous disease of the orbit: clinical presentations, evaluation, and management. Actas Dermosifiliogr 108(5):400\u2013406","DOI":"10.1016\/j.adengl.2017.03.030"},{"key":"3179_CR97","unstructured":"Elner VM et al (2005) Local corticosteroid treatment of eyelid and orbital xanthogranuloma. Trans Am Ophthalmol Soc 103: 69\u201373; discussion 73\u20134"},{"issue":"4","key":"3179_CR98","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/bjo.2006.109587","volume":"91","author":"A Hayden","year":"2007","unstructured":"Hayden A, Wilson DJ, Rosenbaum JT (2007) Management of orbital xanthogranuloma with methotrexate. Br J Ophthalmol 91(4):434\u2013436","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"3179_CR99","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/dth.12135","volume":"27","author":"W Liszewski","year":"2014","unstructured":"Liszewski W et al (2014) Treatment of refractory necrobiotic xanthogranulomas with extracorporeal photopheresis and intravenous immunoglobulin. Dermatol Ther 27(5):268\u2013271","journal-title":"Dermatol Ther"},{"issue":"10","key":"3179_CR100","first-page":"680","volume":"11","author":"M Abdul-Hay","year":"2013","unstructured":"Abdul-Hay M (2013) Immunomodulatory drugs for the treatment of periorbital necrobiotic xanthogranuloma. Clin Adv Hematol Oncol 11(10):680\u2013681","journal-title":"Clin Adv Hematol Oncol"},{"issue":"10","key":"3179_CR101","first-page":"678","volume":"11","author":"S Ghani","year":"2013","unstructured":"Ghani S et al (2013) Periorbital necrobiotic xanthogranuloma treated successfully with novel multiple myeloma therapy. Clin Adv Hematol Oncol 11(10):678\u2013680","journal-title":"Clin Adv Hematol Oncol"},{"issue":"3","key":"3179_CR102","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.clml.2011.03.020","volume":"11","author":"Y Efebera","year":"2011","unstructured":"Efebera Y et al (2011) Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the literature. Clin Lymphoma Myeloma Leuk 11(3):298\u2013302","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"3179_CR103","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.revmed.2014.04.007","volume":"35","author":"J Haroche","year":"2014","unstructured":"Haroche J et al (2014) Erdheim\u2013Chester disease. Rev Med Interne 35(11):715\u2013722","journal-title":"Rev Med Interne"},{"issue":"3","key":"3179_CR104","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jaad.2015.11.007","volume":"74","author":"F Chasset","year":"2016","unstructured":"Chasset F et al (2016) Cutaneous manifestations of Erdheim\u2013Chester disease (ECD): clinical, pathological, and molecular features in a monocentric series of 40 patients. J Am Acad Dermatol 74(3):513\u2013520","journal-title":"J Am Acad Dermatol"},{"key":"3179_CR105","doi-asserted-by":"crossref","unstructured":"Rasc\u00f3n-Ram\u00edrez FJ et al (2016) [Erdheim\u2013Chester disease, an incredible simulator. Cases reports and review of literature]. Neurocirugia (Astur) 27(6):296\u2013303","DOI":"10.1016\/j.neucir.2016.02.009"},{"issue":"1","key":"3179_CR106","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2298\/VSP140915037P","volume":"73","author":"P Peri\u0107","year":"2016","unstructured":"Peri\u0107 P et al (2016) Successful treatment with cladribine of Erdheim\u2013Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis. Vojnosanit Pregl 73(1):83\u201387","journal-title":"Vojnosanit Pregl"},{"issue":"11","key":"3179_CR107","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood-2015-09-672667","volume":"127","author":"F Cohen-Aubart","year":"2016","unstructured":"Cohen-Aubart F et al (2016) Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim\u2013Chester disease. Blood 127(11):1509\u20131512","journal-title":"Blood"},{"issue":"7","key":"3179_CR108","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3109\/0284186X.2015.1120885","volume":"55","author":"F Franconieri","year":"2016","unstructured":"Franconieri F et al (2016) Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim\u2013Chester disease: towards the paradigm of combined targeting and immune therapies. Acta Oncol 55(7):930\u2013932","journal-title":"Acta Oncol"},{"issue":"3","key":"3179_CR109","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/01676830.2022.2087232","volume":"42","author":"JK Park","year":"2023","unstructured":"Park JK, Huang LC, Kossler AL (2023) Erdheim\u2013Chester disease and vemurafenib: a review of ophthalmic presentations and clinical outcomes. Orbit 42(3):233\u2013244","journal-title":"Orbit"},{"issue":"1","key":"3179_CR110","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1177\/11206721221113431","volume":"33","author":"T Alzahem","year":"2023","unstructured":"Alzahem T et al (2023) Ophthalmic histiocytic lesions (diseases of the L group): a multicenter clinicopathological study of 18 cases and review of literature. Eur J Ophthalmol 33(1):556\u2013566","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"3179_CR111","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/bloodadvances.2016001784","volume":"1","author":"JI Estrada-Veras","year":"2017","unstructured":"Estrada-Veras JI et al (2017) The clinical spectrum of Erdheim\u2013Chester disease: an observational cohort study. Blood Adv 1(6):357\u2013366","journal-title":"Blood Adv"},{"issue":"16","key":"3179_CR112","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/blood.2019002766","volume":"135","author":"J Haroche","year":"2020","unstructured":"Haroche J, Cohen-Aubart F, Amoura Z (2020) Erdheim\u2013Chester disease. Blood 135(16):1311\u20131318","journal-title":"Blood"},{"issue":"19","key":"3179_CR113","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2014-04-570937","volume":"124","author":"JF Emile","year":"2014","unstructured":"Emile JF et al (2014) Recurrent RAS and PIK3CA mutations in Erdheim\u2013Chester disease. Blood 124(19):3016\u20133019","journal-title":"Blood"},{"issue":"6","key":"3179_CR114","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1182\/blood-2013-02-482984","volume":"122","author":"EL Diamond","year":"2013","unstructured":"Diamond EL et al (2013) Detection of an NRAS mutation in Erdheim\u2013Chester disease. Blood 122(6):1089\u20131091","journal-title":"Blood"},{"issue":"10","key":"3179_CR115","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2010-10-313510","volume":"117","author":"L Arnaud","year":"2011","unstructured":"Arnaud L et al (2011) Systemic perturbation of cytokine and chemokine networks in Erdheim\u2013Chester disease: a single-center series of 37 patients. Blood 117(10):2783\u20132790","journal-title":"Blood"},{"issue":"7","key":"3179_CR116","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1440929","volume":"7","author":"G Pacini","year":"2018","unstructured":"Pacini G et al (2018) The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim\u2013Chester disease. Oncoimmunology 7(7):e1440929","journal-title":"Oncoimmunology"},{"issue":"6","key":"3179_CR117","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/rheumatology\/kep461","volume":"49","author":"L Dagna","year":"2010","unstructured":"Dagna L et al (2010) Erdheim\u2013Chester disease: report on a case and new insights on its immunopathogenesis. Rheumatology (Oxford) 49(6):1203\u20131206","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"3179_CR118","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.survophthal.2021.05.013","volume":"67","author":"M Kanakis","year":"2022","unstructured":"Kanakis M et al (2022) Erdheim\u2013Chester disease: a comprehensive review from the ophthalmologic perspective. Surv Ophthalmol 67(2):388\u2013410","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"3179_CR119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2015.02.004","volume":"95","author":"M Cives","year":"2015","unstructured":"Cives M et al (2015) Erdheim\u2013Chester disease: a systematic review. Crit Rev Oncol Hematol 95(1):1\u201311","journal-title":"Crit Rev Oncol Hematol"},{"key":"3179_CR120","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ajoc.2018.07.005","volume":"11","author":"LC Huang","year":"2018","unstructured":"Huang LC et al (2018) Orbital and chorioretinal manifestations of Erdheim\u2013Chester disease treated with vemurafenib. Am J Ophthalmol Case Rep 11:158\u2013163","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"Pt 4","key":"3179_CR121","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/eye.2000.151","volume":"14","author":"TG Sheidow","year":"2000","unstructured":"Sheidow TG, Nicolle DA, Heathcote JG (2000) Erdheim\u2013Chester disease: two cases of orbital involvement. Eye (Lond) 14(Pt 4):606\u2013612","journal-title":"Eye (Lond)"},{"issue":"2","key":"3179_CR122","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1148\/radiol.2382041525","volume":"238","author":"E Dion","year":"2006","unstructured":"Dion E et al (2006) Bone involvement in Erdheim\u2013Chester disease: imaging findings including periostitis and partial epiphyseal involvement. Radiology 238(2):632\u2013639","journal-title":"Radiology"},{"issue":"8","key":"3179_CR123","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s002340000351","volume":"42","author":"K Marsot-Dupuch","year":"2000","unstructured":"Marsot-Dupuch K, Le Hir P (2000) Erdheim\u2013Chester disease: a sinonasal lesion mimicking rhinoscleroma. Neuroradiology 42(8):625","journal-title":"Neuroradiology"},{"issue":"4","key":"3179_CR124","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/01676830.2016.1176211","volume":"35","author":"H Merritt","year":"2016","unstructured":"Merritt H et al (2016) Erdheim\u2013Chester disease with orbital involvement: case report and ophthalmic literature review. Orbit 35(4):221\u2013226","journal-title":"Orbit"},{"key":"3179_CR125","first-page":"64","volume":"81","author":"MG Alper","year":"1983","unstructured":"Alper MG, Zimmerman LE, Piana FG (1983) Orbital manifestations of Erdheim\u2013Chester disease. Trans Am Ophthalmol Soc 81:64\u201385","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"6","key":"3179_CR126","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1001\/archopht.1991.01080060114037","volume":"109","author":"JA Shields","year":"1991","unstructured":"Shields JA et al (1991) Orbital and eyelid involvement with Erdheim-Chester disease. A report of two cases. Arch Ophthalmol 109(6):850\u2013854","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"3179_CR127","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1076\/orbi.17.2.97.2758","volume":"17","author":"P de Palma","year":"1998","unstructured":"de Palma P et al (1998) Bilateral orbital involvement in Erdheim\u2013Chester disease. Orbit 17(2):97\u2013105","journal-title":"Orbit"},{"issue":"12","key":"3179_CR128","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1634\/theoncologist.2018-0295","volume":"23","author":"PA Oneal","year":"2018","unstructured":"Oneal PA et al (2018) FDA approval summary: Vemurafenib for the treatment of patients with Erdheim\u2013Chester disease with the BRAFV600 mutation. Oncologist 23(12):1520\u20131524","journal-title":"Oncologist"},{"issue":"7","key":"3179_CR129","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA et al (2017) Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18(7):863\u2013873","journal-title":"Lancet Oncol"},{"issue":"9","key":"3179_CR130","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00296-020-04627-z","volume":"40","author":"O Iaremenko","year":"2020","unstructured":"Iaremenko O et al (2020) Clinical presentation, imaging and response to interferon-alpha therapy in Erdheim\u2013Chester disease: case-based review. Rheumatol Int 40(9):1529\u20131536","journal-title":"Rheumatol Int"},{"issue":"10","key":"3179_CR131","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/art.22165","volume":"54","author":"J Haroche","year":"2006","unstructured":"Haroche J et al (2006) Variability in the efficacy of interferon-alpha in Erdheim\u2013Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum 54(10):3330\u20133336","journal-title":"Arthritis Rheum"},{"key":"3179_CR132","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12916-014-0221-3","volume":"12","author":"RD Mazor","year":"2014","unstructured":"Mazor RD et al (2014) Clinical considerations and key issues in the management of patients with Erdheim\u2013Chester disease: a seven case series. BMC Med 12:221","journal-title":"BMC Med"},{"issue":"12","key":"3179_CR133","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1182\/blood.V93.12.4125","volume":"93","author":"A Saven","year":"1999","unstructured":"Saven A, Burian C (1999) Cladribine activity in adult Langerhans-cell histiocytosis. Blood 93(12):4125\u20134130","journal-title":"Blood"},{"issue":"4","key":"3179_CR134","doi-asserted-by":"crossref","first-page":"E693","DOI":"10.1093\/neuros\/nyz027","volume":"85","author":"JP Marinelli","year":"2019","unstructured":"Marinelli JP et al (2019) Skull base manifestations of Erdheim\u2013Chester disease: a case series and systematic review. Neurosurgery 85(4):E693\u2013E701","journal-title":"Neurosurgery"},{"issue":"4","key":"3179_CR135","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood-2014-03-561381","volume":"124","author":"EL Diamond","year":"2014","unstructured":"Diamond EL et al (2014) Consensus guidelines for the diagnosis and clinical management of Erdheim\u2013Chester disease. Blood 124(4):483\u2013492","journal-title":"Blood"},{"issue":"1","key":"3179_CR136","doi-asserted-by":"crossref","first-page":"81","DOI":"10.5414\/CN107041","volume":"78","author":"MT Chen","year":"2012","unstructured":"Chen MT et al (2012) Pericardial effusion as a crucial presentation of Erdheim\u2013Chester disease in a hemodialysis patient: an overlooked diagnosis. Clin Nephrol 78(1):81\u201384","journal-title":"Clin Nephrol"},{"key":"3179_CR137","first-page":"1030478","volume":"2016","author":"V Arnao","year":"2016","unstructured":"Arnao V et al (2016) Mercaptopurine treatment in an adult man with orbital and intracranial Rosai\u2013Dorfman disease. Case Rep Neurol Med 2016:1030478","journal-title":"Case Rep Neurol Med"},{"issue":"3","key":"3179_CR138","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/10428199209053622","volume":"7","author":"S Sacchi","year":"1992","unstructured":"Sacchi S et al (1992) Sinus histiocytosis with massive lymphadenopathy. Leuk Lymphoma 7(3):189\u2013194","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"3179_CR139","first-page":"1386","volume":"22","author":"E Wang","year":"2001","unstructured":"Wang E et al (2001) Rosai\u2013Dorfman disease presenting with isolated bilateral orbital masses: report of two cases. AJNR Am J Neuroradiol 22(7):1386\u20131388","journal-title":"AJNR Am J Neuroradiol"},{"issue":"3","key":"3179_CR140","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s12105-016-0719-4","volume":"10","author":"E Shukla","year":"2016","unstructured":"Shukla E et al (2016) Extra nodal Rosai\u2013Dorfman disease (sinus histiocytosis with massive lymphadenopathy) presenting as asymmetric bilateral optic atrophy: an atypical ocular presentation. Head Neck Pathol 10(3):414\u2013417","journal-title":"Head Neck Pathol"},{"issue":"3","key":"3179_CR141","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF01626356","volume":"419","author":"F Delacr\u00e9taz","year":"1991","unstructured":"Delacr\u00e9taz F et al (1991) Sinus histiocytosis with massive lymphadenopathy (Rosai Dorfman disease) in an HIV-positive patient. Virchows Arch A Pathol Anat Histopathol 419(3):251\u2013254","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"issue":"2","key":"3179_CR142","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000833","volume":"6","author":"NV Morgan","year":"2010","unstructured":"Morgan NV et al (2010) Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai\u2013Dorfman disease. PLoS Genet 6(2):e1000833","journal-title":"PLoS Genet"},{"issue":"2","key":"3179_CR143","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3324\/haematol.2015.138081","volume":"102","author":"Y Xie","year":"2017","unstructured":"Xie Y et al (2017) Bone marrow findings in autoimmune lymphoproliferative syndrome with germline FAS mutation. Haematologica 102(2):364\u2013372","journal-title":"Haematologica"},{"issue":"2","key":"3179_CR144","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","volume":"6","author":"EL Diamond","year":"2016","unstructured":"Diamond EL et al (2016) Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 6(2):154\u2013165","journal-title":"Cancer Discov"},{"issue":"3","key":"3179_CR145","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s12105-016-0709-6","volume":"10","author":"V Shanmugam","year":"2016","unstructured":"Shanmugam V et al (2016) Rosai\u2013Dorfman disease harboring an activating KRAS K117N missense mutation. Head Neck Pathol 10(3):394\u2013399","journal-title":"Head Neck Pathol"},{"issue":"3","key":"3179_CR146","volume":"2","author":"LH Lee","year":"2017","unstructured":"Lee LH et al (2017) Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI Insight 2(3):e89473","journal-title":"JCI Insight"},{"issue":"10","key":"3179_CR147","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/modpathol.2017.55","volume":"30","author":"S Garces","year":"2017","unstructured":"Garces S et al (2017) Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai\u2013Dorfman disease. Mod Pathol 30(10):1367\u20131377","journal-title":"Mod Pathol"},{"issue":"4","key":"3179_CR148","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00428-017-2173-4","volume":"471","author":"MS Matter","year":"2017","unstructured":"Matter MS et al (2017) Is Rosai\u2013Dorfman disease a reactve process? Detection of a MAP2K1 L115V mutation in a case of Rosai\u2013Dorfman disease. Virchows Arch 471(4):545\u2013547","journal-title":"Virchows Arch"},{"issue":"8","key":"3179_CR149","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.1097\/RLU.0000000000000853","volume":"40","author":"D Albano","year":"2015","unstructured":"Albano D, Bosio G, Bertagna F (2015) 18F-FDG PET\/CT follow-up of Rosai\u2013Dorfman disease. Clin Nucl Med 40(8):e420\u2013e422","journal-title":"Clin Nucl Med"},{"issue":"1","key":"3179_CR150","first-page":"19","volume":"7","author":"E Foucar","year":"1990","unstructured":"Foucar E, Rosai J, Dorfman R (1990) Sinus histiocytosis with massive lymphadenopathy (Rosai\u2013Dorfman disease): review of the entity. Semin Diagn Pathol 7(1):19\u201373","journal-title":"Semin Diagn Pathol"},{"issue":"4","key":"3179_CR151","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.hemonc.2018.05.005","volume":"13","author":"YA Yousef","year":"2020","unstructured":"Yousef YA et al (2020) Rosai\u2013Dorfman disease masquerading as Uveal Melanoma: case report and review of literature. Hematol Oncol Stem Cell Ther 13(4):238\u2013241","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"3179_CR152","doi-asserted-by":"crossref","unstructured":"Yataco-Vicente JA, Araujo-Castillo RV, L\u00f3pez Fuentes MH (2018) Orbital presentation of Rosai\u2013Dorfman disease. Arch Soc Esp Oftalmol (Engl Ed) 93(10):515\u2013518","DOI":"10.1016\/j.oftale.2018.07.007"},{"issue":"1","key":"3179_CR153","first-page":"74","volume":"7","author":"RN Eisen","year":"1990","unstructured":"Eisen RN, Buckley PJ, Rosai J (1990) Immunophenotypic characterization of sinus histiocytosis with massive lymphadenopathy (Rosai\u2013Dorfman disease). Semin Diagn Pathol 7(1):74\u201382","journal-title":"Semin Diagn Pathol"},{"issue":"1","key":"3179_CR154","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ajh.10008","volume":"69","author":"A Pulsoni","year":"2002","unstructured":"Pulsoni A et al (2002) Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai\u2013Dorfman disease): report of a case and literature review. Am J Hematol 69(1):67\u201371","journal-title":"Am J Hematol"},{"issue":"4","key":"3179_CR155","doi-asserted-by":"crossref","first-page":"312","DOI":"10.5581\/1516-8484.20110083","volume":"33","author":"FB Lima","year":"2011","unstructured":"Lima FB et al (2011) Rosai\u2013Dorfman disease with spontaneous resolution: case report of a child. Rev Bras Hematol Hemoter 33(4):312\u2013314","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"3","key":"3179_CR156","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.joms.2015.09.017","volume":"74","author":"TH Al-Khateeb","year":"2016","unstructured":"Al-Khateeb TH (2016) Cutaneous Rosai\u2013Dorfman disease of the face: a comprehensive literature review and case report. J Oral Maxillofac Surg 74(3):528\u2013540","journal-title":"J Oral Maxillofac Surg"},{"issue":"10","key":"3179_CR157","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hed.21832","volume":"34","author":"HH Chen","year":"2012","unstructured":"Chen HH et al (2012) Factors associated with recurrence and therapeutic strategies for sinonasal Rosai\u2013Dorfman disease. Head Neck 34(10):1504\u20131513","journal-title":"Head Neck"},{"issue":"3","key":"3179_CR158","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.prp.2005.11.004","volume":"202","author":"WJ Z'Graggen","year":"2006","unstructured":"Z\u2019Graggen WJ et al (2006) Isolated Rosai\u2013Dorfman disease of intracranial meninges. Pathol Res Pract 202(3):165\u2013170","journal-title":"Pathol Res Pract"},{"issue":"6","key":"3179_CR159","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3109\/15513815.2011.618873","volume":"30","author":"S Shulman","year":"2011","unstructured":"Shulman S et al (2011) Unusual presentation of Rosai\u2013Dorfman disease (RDD) in the bone in adolescents. Fetal Pediatr Pathol 30(6):442\u2013447","journal-title":"Fetal Pediatr Pathol"},{"issue":"2","key":"3179_CR160","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/pbc.25770","volume":"63","author":"SL Cooper","year":"2016","unstructured":"Cooper SL et al (2016) Successful treatment of recurrent autoimmune cytopenias in the context of sinus histiocytosis with massive lymphadenopathy using sirolimus. Pediatr Blood Cancer 63(2):358\u2013360","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"3179_CR161","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0190-9622(97)70186-5","volume":"37","author":"MM Scheel","year":"1997","unstructured":"Scheel MM et al (1997) Sinus histiocytosis with massive lymphadenopathy: presentation as giant granuloma annulare and detection of human herpesvirus 6. J Am Acad Dermatol 37(4):643\u2013646","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3179_CR162","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/106689690501300311","volume":"13","author":"Y Jabali","year":"2005","unstructured":"Jabali Y, Smrcka V, Pradna J (2005) Rosai\u2013Dorfman disease: successful long-term results by combination chemotherapy with prednisone, 6-mercaptopurine, methotrexate, and vinblastine: a case report. Int J Surg Pathol 13(3):285\u2013289","journal-title":"Int J Surg Pathol"},{"key":"3179_CR163","doi-asserted-by":"crossref","unstructured":"Inoue S, Onwuzurike N (2005) Venorelbine and methotrexate for the treatment of Rosai\u2013Dorfman disease. Pediatr Blood Cancer 45(1): 84\u20135; author reply 86","DOI":"10.1002\/pbc.20361"},{"key":"3179_CR164","volume":"2013","author":"AM Maklad","year":"2013","unstructured":"Maklad AM et al (2013) Steroid-resistant extranodal Rosai\u2013Dorfman disease of cheek mass and ptosis treated with radiation therapy. Case Rep Hematol 2013:428297","journal-title":"Case Rep Hematol"},{"issue":"12","key":"3179_CR165","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1001\/jamaoncol.2022.4432","volume":"8","author":"JP Abeykoon","year":"2022","unstructured":"Abeykoon JP et al (2022) Outcomes After treatment with Cobimetinib in patients with Rosai\u2013Dorfman disease based on KRAS and MEK alteration status. JAMA Oncol 8(12):1816\u20131820","journal-title":"JAMA Oncol"},{"issue":"4","key":"3179_CR166","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/00000478-200604000-00014","volume":"30","author":"M Miettinen","year":"2006","unstructured":"Miettinen M, Fetsch JF (2006) Reticulohistiocytoma (solitary epithelioid histiocytoma): a clinicopathologic and immunohistochemical study of 44 cases. Am J Surg Pathol 30(4):521\u2013528","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"3179_CR167","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0161-6420(90)32475-2","volume":"97","author":"GS Allaire","year":"1990","unstructured":"Allaire GS et al (1990) Reticulohistiocytoma of the limbus and cornea. A clinicopathologic study of two cases. Ophthalmology 97(8):1018\u20131022","journal-title":"Ophthalmology"},{"issue":"3","key":"3179_CR168","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0161-6420(95)31005-6","volume":"102","author":"RC Eagle Jr","year":"1995","unstructured":"Eagle RC Jr, Penne RA, Hneleski IS Jr (1995) Eyelid involvement in multicentric reticulohistiocytosis. Ophthalmology 102(3):426\u2013430","journal-title":"Ophthalmology"},{"issue":"11","key":"3179_CR169","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1001\/archophthalmol.2011.314","volume":"129","author":"FA Jakobiec","year":"2011","unstructured":"Jakobiec FA et al (2011) Solitary epithelioid histiocytoma (reticulohistiocytoma) of the eyelid. Arch Ophthalmol 129(11):1502\u20131504","journal-title":"Arch Ophthalmol"},{"key":"3179_CR170","doi-asserted-by":"crossref","unstructured":"Favara BE et al (1997) Contemporary classification of histiocytic disorders. The WHO committee on histiocytic\/reticulum cell proliferations. Reclassification working group of the Histiocyte society. Med Pediatr Oncol 29(3):157\u2013166","DOI":"10.1002\/(SICI)1096-911X(199709)29:3<157::AID-MPO1>3.0.CO;2-C"},{"issue":"1","key":"3179_CR171","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1097\/IOP.0000000000000024","volume":"31","author":"HM Weissman","year":"2015","unstructured":"Weissman HM, Hayek BR, Grossniklaus HE (2015) Reticulohistiocytoma of the orbit. Ophthalmic Plast Reconstr Surg 31(1):e13\u2013e16","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"3179_CR172","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/03009740252937658","volume":"31","author":"JJ Blanco","year":"2002","unstructured":"Blanco JJ et al (2002) Multicentric reticulohistiocytosis. The long course of a rare disease. Scand J Rheumatol 31(2):107\u2013109","journal-title":"Scand J Rheumatol"},{"issue":"9","key":"3179_CR173","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/archderm.141.9.1167-b","volume":"141","author":"K Lovelace","year":"2005","unstructured":"Lovelace K et al (2005) Etanercept and the treatment of multicentric reticulohistiocytosis. Arch Dermatol 141(9):1167\u20131168","journal-title":"Arch Dermatol"},{"issue":"3","key":"3179_CR174","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.10781","volume":"48","author":"C Matejicka","year":"2003","unstructured":"Matejicka C, Morgan GJ, Schlegelmilch JG (2003) Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum 48(3):864\u2013866","journal-title":"Arthritis Rheum"},{"issue":"5","key":"3179_CR175","doi-asserted-by":"crossref","first-page":"384","DOI":"10.7326\/0003-4819-111-5-384","volume":"111","author":"WW Ginsburg","year":"1989","unstructured":"Ginsburg WW et al (1989) Multicentric reticulohistiocytosis: response to alkylating agents in six patients. Ann Intern Med 111(5):384\u2013388","journal-title":"Ann Intern Med"},{"issue":"2","key":"3179_CR176","first-page":"71","volume":"47","author":"C Vital","year":"1999","unstructured":"Vital C et al (1999) Brain stem infiltration by mixed Langerhans cell histiocytosis and Chester\u2013Erdheim disease: more than just an isolated case? Clin Exp Pathol 47(2):71\u201376","journal-title":"Clin Exp Pathol"},{"issue":"7","key":"3179_CR177","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood-2013-12-543793","volume":"124","author":"B Hervier","year":"2014","unstructured":"Hervier B et al (2014) Association of both Langerhans cell histiocytosis and Erdheim\u2013Chester disease linked to the BRAFV600E mutation. Blood 124(7):1119\u20131126","journal-title":"Blood"},{"issue":"1","key":"3179_CR178","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/10428194.2020.1824070","volume":"62","author":"A Bonometti","year":"2021","unstructured":"Bonometti A (2021) The triptych of mixed histiocytosis: a systematic review of 105 cases and proposed clinical classification. Leuk Lymphoma 62(1):32\u201344","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"3179_CR179","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1148\/radiology.151.1.6608118","volume":"151","author":"AC Brower","year":"1984","unstructured":"Brower AC, Worsham GF, Dudley AH (1984) Erdheim\u2013Chester disease: a distinct lipoidosis or part of the spectrum of histiocytosis? Radiology 151(1):35\u201338","journal-title":"Radiology"},{"key":"3179_CR180","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/archderm.1963.01590140026004","volume":"87","author":"J Altman","year":"1963","unstructured":"Altman J, Winkelmann RK (1963) Xanthomatous cutaneous lesions of histiocytosis X. Arch Dermatol 87:164\u2013170","journal-title":"Arch Dermatol"},{"issue":"3","key":"3179_CR181","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/cup.12636","volume":"43","author":"WT Johnson","year":"2016","unstructured":"Johnson WT et al (2016) Langerhans cell histiocytosis and Erdheim\u2013Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation. J Cutan Pathol 43(3):270\u2013275","journal-title":"J Cutan Pathol"},{"issue":"4","key":"3179_CR182","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/bjd.17420","volume":"180","author":"F Bellinato","year":"2019","unstructured":"Bellinato F et al (2019) BRAF V600E expression in juvenile xanthogranuloma occurring after Langerhans cell histiocytosis. Br J Dermatol 180(4):933\u2013934","journal-title":"Br J Dermatol"},{"issue":"1","key":"3179_CR183","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3171\/2018.6.PEDS17728","volume":"23","author":"X Hao","year":"2018","unstructured":"Hao X et al (2018) Dramatic efficacy of dabrafenib in Erdheim\u2013Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis. J Neurosurg Pediatr 23(1):48\u201353","journal-title":"J Neurosurg Pediatr"},{"issue":"1","key":"3179_CR184","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000078589","volume":"209","author":"A Patrizi","year":"2004","unstructured":"Patrizi A et al (2004) Langerhans cell histiocytosis and juvenile xanthogranuloma. Two case reports. Dermatology 209(1):57\u201361","journal-title":"Dermatology"},{"issue":"3","key":"3179_CR185","first-page":"475","volume":"143","author":"AC Chu","year":"2000","unstructured":"Chu AC (2000) The confusing state of the histiocytoses. Br J Dermatol 143(3):475\u2013476","journal-title":"Br J Dermatol"},{"issue":"4","key":"3179_CR186","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1046\/j.1365-2133.2002.04879.x","volume":"147","author":"KH Wang","year":"2002","unstructured":"Wang KH et al (2002) Coexistence of localized Langerhans cell histiocytosis and cutaneous Rosai\u2013Dorfman disease. Br J Dermatol 147(4):770\u2013774","journal-title":"Br J Dermatol"},{"issue":"2","key":"3179_CR187","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/pbc.24379","volume":"60","author":"O Abla","year":"2013","unstructured":"Abla O et al (2013) Central nervous system juvenile xanthogranuloma after langerhans cell histiocytosis. Pediatr Blood Cancer 60(2):342\u2013343","journal-title":"Pediatr Blood Cancer"},{"key":"3179_CR188","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2147\/OTT.S121615","volume":"10","author":"Z V\u00e1radi","year":"2017","unstructured":"V\u00e1radi Z et al (2017) Effective BRAF inhibitor vemurafenib therapy in a 2-year-old patient with sequentially diagnosed Langerhans cell histiocytosis and Erdheim\u2013Chester disease. Onco Targets Ther 10:521\u2013526","journal-title":"Onco Targets Ther"},{"key":"3179_CR189","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12907-017-0044-1","volume":"17","author":"B Efared","year":"2017","unstructured":"Efared B et al (2017) Bone pathologic fracture revealing an unusual association: coexistence of Langerhans cell histiocytosis with Rosai\u2013Dorfman disease. BMC Clin Pathol 17:5","journal-title":"BMC Clin Pathol"},{"issue":"12","key":"3179_CR190","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/modpathol.2010.157","volume":"23","author":"DP O'Malley","year":"2010","unstructured":"O\u2019Malley DP et al (2010) Co-occurrence of Langerhans cell histiocytosis and Rosai\u2013Dorfman disease: possible relationship of two histiocytic disorders in rare cases. Mod Pathol 23(12):1616\u20131623","journal-title":"Mod Pathol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03179-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-024-03179-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03179-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:38:09Z","timestamp":1741880289000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-024-03179-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":190,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3179"],"URL":"https:\/\/doi.org\/10.1007\/s10792-024-03179-6","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"13 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"236"}}